121 related articles for article (PubMed ID: 1487125)
21. Increased arterial distensibility induced by the angiotensin-converting enzyme inhibitor, lisinopril, in normotensive rats.
Makki T; Talom RT; Niederhoffer N; Amin F; Tankosic P; Mertès PM; Atkinson J
Br J Pharmacol; 1994 Feb; 111(2):555-60. PubMed ID: 8004398
[TBL] [Abstract][Full Text] [Related]
22. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade.
Warltier DC; Zyvoloski MG; Gross GJ; Brooks HL
J Pharmacol Exp Ther; 1984 Aug; 230(2):367-75. PubMed ID: 6146711
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular effects of budralazine in the dog.
Chiba S; Saegusa K; Furukawa Y; Ogiwara Y
Jpn Heart J; 1986 May; 27(3):403-11. PubMed ID: 3761571
[TBL] [Abstract][Full Text] [Related]
24. Effects of hydralazine on adrenal and cardiac sympathetic nerve activity in anesthetized rats.
Yoshioka M; Togashi H; Minami M; Saito H
Res Commun Chem Pathol Pharmacol; 1986 Dec; 54(3):313-20. PubMed ID: 3797810
[TBL] [Abstract][Full Text] [Related]
25. The influence of cyclo-oxygenase inhibitors on the cardiovascular effects of hydralazine in rats.
Vidrio H; Garcia-Marquez F
Arch Int Pharmacodyn Ther; 1985 Jan; 273(1):131-41. PubMed ID: 3923959
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.
Einstein R; Abdul-Hussein N; Wong TW; Chang DH; Matthews R; Richardson DP
Br J Pharmacol; 1994 Jan; 111(1):199-204. PubMed ID: 7912154
[TBL] [Abstract][Full Text] [Related]
27. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
Anderson IK; Drew GM
Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
[TBL] [Abstract][Full Text] [Related]
28. Direct effects of hydralazine on cardiac contractile function, haemodynamics, and myocardial energetics in isolated myocardium.
Rendig SV; Segel LD; Amsterdam EA
Cardiovasc Res; 1988 May; 22(5):322-8. PubMed ID: 3191517
[TBL] [Abstract][Full Text] [Related]
29. The anti-tachycardic mechanism of a direct-acting vasodilator, budralazine, in rats.
Yoshioka M; Minami M; Saito H
Clin Exp Hypertens A; 1991; 13(5):1107-14. PubMed ID: 1773498
[TBL] [Abstract][Full Text] [Related]
30. Positive inotropic action of angiotensin II in the pithed rat.
Zhang J; Pfaffendorf M; van Zwieten PA
Naunyn Schmiedebergs Arch Pharmacol; 1993 Jun; 347(6):658-63. PubMed ID: 8103195
[TBL] [Abstract][Full Text] [Related]
31. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile.
Dukes ID; Vaughan Williams EM
Br J Pharmacol; 1985 Feb; 84(2):365-80. PubMed ID: 2858236
[TBL] [Abstract][Full Text] [Related]
33. Effects of beta blocking agents on the cardiovascular action of hydralazine in conscious rats.
Kubo T; Yamashita M; Misu Y
Jpn J Pharmacol; 1981 Dec; 31(6):1087-90. PubMed ID: 6121071
[No Abstract] [Full Text] [Related]
34. Direct positive chronotropic effects of angiotensin II and angiotensin III in pithed rats and in rat isolated atria.
Li Q; Zhang J; Pfaffendorf M; van Zwieten PA
Br J Pharmacol; 1996 Aug; 118(7):1653-8. PubMed ID: 8842428
[TBL] [Abstract][Full Text] [Related]
35. Naloxone's effect on the inotropic and chronotropic responses of isolated, electrically stimulated or spontaneously beating rat atria.
Thornhill J; St Onge R; Gregor L
Can J Physiol Pharmacol; 1990 Mar; 68(3):392-401. PubMed ID: 2322896
[TBL] [Abstract][Full Text] [Related]
36. Hypotensive and antihypertensive effects of a hydroalcoholic extract from Senecio nutans Sch. Bip. (Compositae) in mice: Chronotropic and negative inotropic effect, a nifedipine-like action.
Cifuentes F; Paredes A; Palacios J; Muñoz F; Carvajal L; Nwokocha CR; Morales G
J Ethnopharmacol; 2016 Feb; 179():367-74. PubMed ID: 26724424
[TBL] [Abstract][Full Text] [Related]
37. Hydralazine and its metabolites: in vitro and in vivo activity in the rat.
Criscione L; Eichenberger K; Hedwall PR; Schmid K
J Cardiovasc Pharmacol; 1986; 8(2):420-7. PubMed ID: 2422484
[TBL] [Abstract][Full Text] [Related]
38. Inhibition by hydralazine of the conversion of dopamine to noradrenaline in rat atria in vitro and in vivo.
Songkittiguna P; Majewski H; Rand MJ
Clin Exp Pharmacol Physiol; 1980; 7(5):509-14. PubMed ID: 7449192
[TBL] [Abstract][Full Text] [Related]
39. Baroreflex sensitivity as a determinant of responses to hydralazine in dogs.
Vidrio H
J Pharmacol Exp Ther; 1983 Jan; 224(1):247-51. PubMed ID: 6848745
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats.
Sim MF; Yates DB; Parkinson R; Cooling MJ
Br J Pharmacol; 1988 Jun; 94(2):371-80. PubMed ID: 3293682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
